Introduction {#S1}
============

In obesity, adipose tissue macrophages (ATM) play a key role in adipose tissue (AT) inflammation and subsequent development of obesity-associated pathologies, such as local and systemic insulin resistance ([@B1], [@B2]). More specifically, circulating monocytes accumulate in obese AT, particularly in visceral depots, wherein they differentiate into ATM to help with tissue remodeling and lipid homeostasis ([@B3]--[@B5]). Importantly, paracrine interactions, or cross-talk, between adipocytes and ATM play a key role in determining macrophage polarization status (i.e. M1 or M2) and the resultant AT secretory profile. Many ATM exhibit an inflammatory M1 phenotype, characterized by increased lipid content, NLRP3 inflammasome activation, expression of the integrin (CD11b) and high levels of anti-microbicidal iNOS (murine only), antigen presentation via MHCII, and secretion of inflammatory cytokines, such as TNFα and IL-6 ([@B6]--[@B9]). Mechanistically, TNFα and IL-6 feedback onto adipocytes through paracrine signaling to sustain secretion of adipocyte-derived inflammatory mediators (e.g., CCL2, IL-6) and release of fatty acids through lipolysis ([@B10]). Finally, some ATM exhibit a less inflammatory M2 phenotype, characterized by surface expression of scavenging receptors, such as CD206, antigen presentation, and secretion of the anti-inflammatory cytokine, IL-10 ([@B6]).

Obesity is also characterized by increased circulating levels of gut bacteria-derived lipopolysaccharide (LPS), a condition termed as metabolic endotoxemia ([@B11]), which leads to LPS accumulation in AT ([@B4]). While some macrophages can exhibit endotoxin tolerance or hypo-responsiveness when re-stimulated with LPS ([@B12]), it is unclear if this occurs in macrophages within obese AT. Interestingly, both the full-length ([@B13]--[@B15]) and globular ([@B16]--[@B18]) isoforms of the anti-inflammatory adipokine, adiponectin (Ad), have been shown to promote a response similar to endotoxin tolerance and macrophage polarization toward the M2 phenotype, or enhance M2 polarization *in vitro* ([@B19]) and *in vivo* ([@B20]). Therefore, Ad could potentially serve to re-direct the cyclic inflammatory cross-talk between adipocytes and M1 macrophages in obesity.

Given the impact of the ATM phenotype on subsequent inflammatory processes and AT dysfunction, strategies to alter ATM polarization status may be useful in mitigating obesity-related inflammation. Of interest, dietary long-chain polyunsaturated fatty acids (LC n-3 PUFA), such as eicosapentaenoic acid (20:5 n-3, EPA) and docosahexaenoic acid (22:6 n-3, DHA), are well-known anti-inflammatory agents ([@B21], [@B22]) and can serve to mitigate excessive inflammatory adipocyte--macrophage paracrine interactions *in vitro* ([@B23], [@B24]). Although it has been shown that LC n-3 PUFA lessen inflammatory adipokine secretion ([@B25]) and M1 macrophage polarization in obese rodent AT ([@B26]--[@B29]), the mechanisms by which this occurs are unclear. Furthermore, while LC n-3 PUFA upregulate secretion of Ad in murine ([@B30]) and human adipocytes ([@B31]), it is unclear if Ad partly mediates the anti-inflammatory effects of LC n-3 PUFA.

Thus, to assess the potential role of Ad in LC n-3 PUFA-mediated anti-inflammatory effects on ATMs, we used an established *ex vivo* AT organ culture method ([@B32]) composed of visceral AT from mice fed a control (CON) safflower oil-derived n-6 PUFA-rich diet or a fish oil (FO)-derived LC n-3 PUFA-rich diet to generate AT conditioned media (ACM). We then evaluated if CON or FO ACM affected macrophage polarization markers in an acute inflammation model in the absence or presence of Ad-neutralizing antibody. Second, we used a low-grade chronic inflammation model whereby visceral AT organ cultures from CON and FO diet fed mice were challenged with LPS *ex vivo* for 24 h prior to incubation with macrophages to mimic the chronic inflammation of metabolic endotoxemia ([@B11], [@B33]). Additionally, we utilized both an Ad-neutralizing antibody and the LPS-neutralizing agent, polymyxin B, to assess if Ad or LPS driven mechanisms affect LC n-3 PUFA-mediated anti-inflammatory effects in macrophages treated with ACM in the chronic inflammation model.

Materials and Methods {#S2}
=====================

Animals and Diets {#S2-1}
-----------------

All experimental procedures were approved by the University of Guelph Animal Care Committee. Mice were housed as described ([@B34]). Eight-week-old male C57BL/6 mice were fed *ad libitum* an AIN-93G modified diet containing either 10% w/w safflower oil (CON) or an isocaloric LC n-3 PUFA-enriched diet containing 3% w/w menhaden oil + 7% w/w safflower oil (FO) for 4 weeks (*n* = 5 mice/diet), \[Research Diets Inc., USA; composition previously reported ([@B34])\]. To prevent diet oxidation the common food anti-oxidant, *t*-Butylhydroquinone, was added to the diets, diets were stored at −20°C prior to use, and mouse food was changed every 2 days to limit oxidation. The FO diet contained approximately 1.7% kcal from LC n-3 PUFA, which is in line with the human dietary recommended intake of 0.5--2% kcal for total n-3 PUFA ([@B35]).

Tissue Collection and AT Organ Culture {#S2-2}
--------------------------------------

Mice were terminated by CO~2~ asphyxiation followed by cervical dislocation. Epididymal fat pads were isolated and immediately placed into 50 mL sterile conical tubes containing 1× PBS (Sigma, USA). Fat pads were blotted dry, approximately cut into two equal portions, and then weighed. Tissue was divided into two per depot so that one sample could be challenged with low-dose LPS (10 ng/mL) from *E. coli* serotype 055:B5 (Sigma, USA, cell culture tested, one lot used) intended to mimic the 5--6 endotoxin units reported in metabolic endotoxemia ([@B11], [@B33]). Immediately after weighing, fat pads were moved to 15 mL sterile conical tubes containing 3 mL of DMEM high glucose (without sodium pyruvate, HyClone, USA) supplemented with 0.5% v/v fetal bovine serum (sterile filtered, Canadian origin, Sigma, USA); a source of anti-oxidants *in vitro* ([@B36]), and 1% v/v penicillin--streptomycin (HyClone, USA). Each tissue sample was immediately minced using sterile scissors into ≤0.5 cm pieces to avoid tissue hypoxia. Under sterile conditions, media was then topped up so that the ratio of tissue to media was at the optimal ratio of 500 mg/15 mL media as reported in the optimized method elsewhere ([@B32]). To the tissues challenged with LPS, an LPS working solution was added to the culture media such that the final concentration was 10 ng/mL. AT samples were placed into 100 mm sterile culture dishes (Sarstedt, USA) and then cultures were placed in a humidified incubator for 24 h at 37°C with 5% CO~2~. Twenty-four hours were chosen since secreted cytokines were elevated between 12 and 24 h (Figure [1](#F1){ref-type="fig"}). After the incubation period, the minced AT was removed using 70 μm sterile cell strainers (BD Biosciences, USA), and the ACM was aliquoted and stored at −80°C until further analysis.

![**Time course secretion of adipokines from CON and FO ACM at 12 and 24 h**. The secretion of M1-associated adipokines IL-6, TNFα, CCL2, CCL5, CCL7 **(A)** and adiponectin **(B)** from CON and FO ACM at 12 and 24 h time points ± LPS challenge. AT organ cultures from epididymal AT of CON or FO fed mice were treated with or without low-dose LPS (10 ng/mL) for 24 h. Data show the means ± SEM for CON and FO (*n* = 5/diet/condition). Bars not sharing a letter are significantly different (*p* ≤ 0.05).](fnut-02-00031-g001){#F1}

Preparation of Macrophage ACM Treatments {#S2-3}
----------------------------------------

The ACM was thawed once and then sterile filtered (0.22 μm, Sarstedt, USA) prior to use. Before incubation with macrophages, 5 μg/mL of Ad-neutralizing antibody (AF1119, anti-mAcrp30, R&D Systems, USA) or isotype control anti-goat IgG (5 μg/mL, R&D Systems, USA) was added to ACM. The samples were then incubated at 4°C as previously reported ([@B37]). This antibody was chosen since it has been reported to suppress Ad-mediated signaling in adipocyte-conditioned media ([@B37], [@B38]), and we confirmed the dose of antibody used suppressed Ad-mediated signaling in pilot experiments with adipocyte-conditioned media (data not shown). In the acute inflammation model (Figures [2](#F2){ref-type="fig"}--[4](#F4){ref-type="fig"}), macrophages were pre-treated with ACM from CON or FO fed mice (no LPS) for 18 h, followed by the addition of LPS (10 ng/mL) to the ACM for the final 6 h (total 24 h). This time course was chosen since both globular ([@B18]) and full-length Ad ([@B15]) have previously been shown to promote a response similar to endotoxin tolerance using a comparable time course. In the chronic inflammation model (Figures [5](#F5){ref-type="fig"}--[7](#F7){ref-type="fig"}), visceral AT organ cultures from CON and FO diet fed mice were challenged with LPS *ex vivo* for 24 h prior to incubation with macrophages for an additional 24 h. Ad-neutralizing antibody was added to ACM as described above. Additionally, the LPS-neutralizing agent, polymyxin B (36 μM, 0.22 μm sterile filtered, cell-culture tested, Sigma, USA), was added to some ACM treatments with gentle vortexing every 10 min for a total of 30 min prior to administering ACM to macrophages at 37°C. For all experiments, macrophages treated with media containing 5 μg/mL IgG plus 10 ng/mL LPS served as the control.

![**Neutral lipid and total lipid profile in macrophages in the acute inflammation model**. Macrophages were treated with CON or FO ACM (no LPS) for 18 h, followed by the addition of low-dose LPS (10 ng/mL) for the last 6 h (24 h total). 5 μg/mL of anti-Ad or IgG were added to ACM treatments prior to culture with macrophages. Macrophages treated with media and 5 μg/mL IgG plus LPS served as the control. Data show the means ± SEM (*n* = 5/diet/condition). Bars not sharing a letter are significantly different (*p* ≤ 0.05).](fnut-02-00031-g002){#F2}

Culture of RAW 264.7 Macrophages {#S2-4}
--------------------------------

RAW 264.7 murine macrophages (ATCC, USA) were grown and passaged according to the manufacturer's instructions. Macrophages were maintained in DMEM high glucose (without sodium pyruvate, HyClone, USA), plus 10% v/v fetal bovine serum (low-endotoxin, Canadian origin, Sigma, USA), and 1% v/v penicillin streptomycin (HyClone, USA). Four hours prior to experiments, macrophages were split using the manufacturer's protocol, counted using trypan exclusion, spun down at 335 × *g* at ambient temperature for 5 min, and then re-suspended in DMEM high glucose plus 0.5% v/v FBS and 1% v/v penicillin streptomycin. Next, the cell density was adjusted to 1.0 × 10^6^ cells/mL and macrophages were seeded into 96-well (for oil red O procedure) or 24-well plates (for RNA/protein analysis) (Corning, USA). Without disturbing the adherent macrophages, media was replaced with the aforementioned control, CON or FO ACM treatments.

Gene Expression {#S2-5}
---------------

After 24 h, cells were washed with 1× PBS, lysed using a RNA/Protein Isolation Kit (Norgen Biotek, Canada), and processed according to the manufacturer's instructions. cDNA was made from 1 μg of extracted RNA using a high capacity cDNA reverse transcription kit as per the manufacturer's instructions (Applied Biosystems, USA). Real-time PCR analysis was performed using a 7900HT Fast Real-Time PCR system (Applied Biosystems, USA) using the default protocol described elsewhere ([@B23]). Primers were designed using the Universal Probe Library Assay Design Center (Roche Applied Sciences, Germany, Table [1](#T1){ref-type="table"}) and validated primer efficiencies were between 90 and 105%. All results were normalized to *18S* mRNA expression, and the relative differences in gene expression between treatment groups and the IgG control (no LPS) were determined using the ΔΔCt method.

###### 

**Primer sequences**.

  Gene name   Forward primer (5′--3′)     Reverse primer (3′--5′)
  ----------- --------------------------- ----------------------------
  *18S*       ACGGAAGGGCACCACCAGGA        CACCACCACCCACGGAATCG
  *Casp1*     CCCACTGCTGATAGGGTGAC        GCATAGGTACATAAGAATGAACTGGA
  *Ccl2*      GCCTGCTGTTCACAGTTGC         CAGGTGAGTGGGGCGTTA
  *Ccl5*      TCCAATCTTGCAGTCGTGTTTG      TCTGGGTTGGCACACACTTG
  *Cd206*     CCACAGCATTGAGGAGTTTG        ACAGCTCATCATTTGGCTCA
  *Cd74*      CGCCCTAGAGAGCCAGAAA         TTGCTGGTACAGGAAGTAAGCA
  *Cd80*      TCGTCTTTCACAAGTGTCTTCAG     TTGCCAGTAGATTCGGTCTTC
  *Cd86*      GAAGCCGAATCAGCCTAGC         CAGCGTTACTATCCCGCTCT
  *Il6*       AACGATGATGCACTTGCAGA        GAGCATTGGAAATTGGGGTA
  *Il10*      GGTTGCCAAGCCTTATCGGA        ACCTGCTCCACTGCCTTGCT
  *Il1*β      AGTTGACGGACCCCAAAAG         AGCTGGATGCTCTCATCAGG
  *Il18*      CAAACCTTCCAAATCACTTCCT      TCCTTGAAGTTGACGCAAGA
  *Itgam*     AGCCCCACACTAGCATCAA         TCCATGTCCACAGAGCAAAG
  *Nf*κ*b*    GAGACCGGCAACTCAAGAC         CTCAGGTCCATCTCCTTGGGT
  *Nlrp3*     CCCTTGGAGACACAGGACTC        GAGGCTGCAGTTGTCTAATTCC
  *Nos2*      TCCTGTTGTTTCTATTTCCTTTGTT   CATCAACCAGTATTATGGCTCCT
  *Tnf*α      CATCTTCTCAAAATTCGAGTGACAA   TGGGAGTAGACAAGGTACAACCC

Secreted Adipokine Analyses {#S2-6}
---------------------------

Supernatant was collected after 12 and 24 h from ACM, and after 24 h following ACM culture with macrophages for analysis of secreted cytokine concentrations. CCL2 (MCP-1), CCL5 (RANTES), CCL7 (MCP-3), IL-4, IL-6, IL-10, IL-18, IL-1β, and TNFα were multiplexed using the ProcartaPlex Mouse Basic kit (eBioscience, USA) using undiluted supernatant and analyzed using the Bio-Plex 200 System (Bio-Rad, USA). To calculate the secretion of adipokines solely from macrophages after 24 h treatment with ACM, the concentration of cytokine measured in ACM prior to culture with macrophages was subtracted from the concentration of cytokine measured after the incubation. Importantly, cell protein and secreted levels of IL-1β and IL-18 were below the minimum detection threshold for all treatments. Additionally, secreted full-length Ad was diluted 100-fold and measured by ELISA (Quantikine Mouse Ad/Acrp 30 ELISA, R&D Systems, USA) according to the manufacturer's instructions.

Macrophage Fatty Acid Composition {#S2-7}
---------------------------------

Following 24 h, macrophages were scraped in 1× PBS and then centrifuged at 335 × *g* at ambient temperature for 10 min. The PBS was aspirated and the pellet was frozen at −80°C until further processing. Total lipids were extracted from cell lysates of macrophages and fatty acid methyl esters were prepared for analysis by gas liquid chromatography as described previously ([@B39], [@B40]). Fatty acids were identified by comparing the retention times of samples with those of a known standard (GLC463; Nu-Chek Prep, USA). Fatty acid composition values are expressed as a percentage of total fatty acids. Within each ACM treatment, the lipid profile between macrophages treated with Ad-neutralizing antibody to those treated with IgG did not differ; therefore, only ACM treatments (IgG) are shown (Figures [2](#F2){ref-type="fig"} and [5](#F5){ref-type="fig"}).

Macrophage Oil Red O Procedure {#S2-8}
------------------------------

Following the 24 h ACM treatment, neutral lipid deposition was assessed in macrophages with minor modification from the original procedure ([@B41]). Briefly, an oil red O working solution was made 6 h in advance by mixing 6 parts oil red O saturate (0.5 g in 100 mL isopropyl alcohol) in 4 parts ddH~2~O, and then filtered twice immediately before use. Next, media was aspirated and cells were then rinsed with 1× PBS. Cultures were fixed with 4% paraformaldehyde solution followed by light shaking at ambient temperature for 10 min. Cultures were then sequentially rinsed with 1× PBS and 70% ethanol before staining with oil red O working solution for 30 min (at ambient temp with light shaking). Following this, cultures were then rinsed again with 1× PBS, then 70% ethanol solution. The solutions were then aspirated and the plate was inverted to dry in a laminar flow hood for 30 min. Next, 200 μL of isopropyl alcohol was added to each well. The plate was sealed, shook lightly for 3 min, and then read immediately with a spectrophotometer at 520 nm. Wells without cells that received the aforementioned staining procedure served as the plate blank. Data are reported as the fold change in absorbance (per treatment) relative to the average absorbance for cells cultured in media without LPS or other additives (*n* = 4).

Statistical Analysis {#S2-9}
--------------------

All data are expressed as mean ± SEM. The predetermined upper limit of probability for statistical significance was *p* ≤ 0.05 and analyses were conducted using SigmaPlot version 12.5 (USA). Data that were not normally distributed were transformed prior to statistical analysis, and normal distribution and equal variance were confirmed by Shapiro--Wilk test and Levene's test, respectively. Data were analyzed using a two-way ANOVA followed, if justified, by testing using Fisher's Least Squared Difference *post hoc* test. Mouse parameters comparing CON and FO diets (Table [2](#T2){ref-type="table"}) and macrophage lipid content between CON and FO ACM (Figures [2](#F2){ref-type="fig"} and [5](#F5){ref-type="fig"}) were analyzed using unpaired *t*-tests.

###### 

**Mouse physiological parameters[^a^](#tfn1){ref-type="table-fn"}**.

  Parameter                       CON           FO
  ------------------------------- ------------- -------------
  Initial body weight (g)         21.0 ± 0.63   21.8 ± 0.52
  Terminal body weight (g)        25.0 ± 2.2    27.5 ± 1.2
  Food intake (g/day)             2.24 ± 0.04   2.22 ± 0.03
  Epididymal fat pad weight (g)   1.36 ± 0.27   1.45 ± 0.15

*^a^Values are means ± SEM (n = 5/dietary group)*.

Results {#S3}
=======

Mouse Parameters {#S3-1}
----------------

Mouse initial and terminal body weights, dietary food intake, and epididymal fat pad weights did not differ between mice fed CON or FO diets (*p* \> 0.05, Table [2](#T2){ref-type="table"}). Previous studies using these diets showed that LC n-3 PUFA are significantly enriched in liver and red blood cells ([@B42]).

ACM Secretory Profile After 24 h With or Without LPS {#S3-2}
----------------------------------------------------

In CON ACM, IL-6, TNFα, CCL2, CCL5, and CCL7 secretion increased in the presence of LPS at both 12 and 24 h (Figure [1](#F1){ref-type="fig"}). Similarly, in FO ACM, IL-6, CCL2, and CCL5 secretion increased when LPS was added at both 12 and 24 h; however, TNFα secretion only increased at 24 h (*p* ≤ 0.05, Figure [1](#F1){ref-type="fig"}). Moreover, in FO ACM, secretion of CCL7 did not change over time or with LPS (*p* \> 0.05, Figure [1](#F1){ref-type="fig"}). Interestingly, in FO ACM without LPS, the secretion of IL-6, TNFα, CCL2, and CCL5 were decreased relative to CON ACM at both 12 and 24 h; however, CCL7 was only decreased at 24 h (*p* ≤ 0.05, Figure [1](#F1){ref-type="fig"}). Similarly, relative to CON ACM with LPS, in FO ACM with LPS the secretion of IL-6 was decreased at both 12 and 24 h, although the secretion of other adipokines was only decreased at one time point (CCL2, CCL5, and CCL7 at 24 h; TNFα at 12 h), (*p* ≤ 0.05, Figure [1](#F1){ref-type="fig"}). Furthermore, the secretion of full-length Ad in ACM did not vary with diet or LPS (*p* \> 0.05, Figure [1](#F1){ref-type="fig"}). Finally, IL-1β, IL-18, IL-4, and IL-10 concentrations were below the range of detection in all ACM treatments.

Lipid Profile in Macrophages Treated With ACM in the Acute Inflammation Model {#S3-3}
-----------------------------------------------------------------------------

To examine if the Ad within ACM from CON or FO fed mice could promote a response similar to endotoxin tolerance, macrophages were pre-treated with ACM or media for 18 h with Ad-neutralizing antibody (anti-Ad) or control IgG, then LPS was added for 6 h for a total of 24 h. First, we measured total lipid uptake using oil red O staining to measure the relative abundance of neutral lipids, and then quantified the percent of total lipids (n-3 and n-6 PUFA, MUFA, and SFA) within the macrophages treated for 24 h with CON or FO ACM (Figure [2](#F2){ref-type="fig"}). Here, without LPS, macrophages treated with CON ACM had increased neutral lipid relative to control (*p* ≤ 0.05); however, no such increase occurred in macrophages treated with FO ACM (*p* \> 0.05, Figure [2](#F2){ref-type="fig"}). Second, adding LPS resulted in an increase in neutral lipid in control macrophages (*p* ≤ 0.05, Figure [2](#F2){ref-type="fig"}). However, levels of neutral lipid did not change when LPS was added in macrophages treated with CON or FO ACM (*p* \> 0.05, Figure [2](#F2){ref-type="fig"}). Interestingly, when LPS was added to ACM with anti-Ad, levels of neutral lipid increased in macrophages treated with FO ACM (*p* ≤ 0.05), but not CON ACM (*p* \> 0.05, Figure [2](#F2){ref-type="fig"}). Finally, the percent of n-3 PUFA (0.24 ± 0.04%), n-6 PUFA (0.33 ± 0.03%), MUFA (4.30 ± 0.24%) and SFA (95.2 ± 0.22%) did not differ in macrophages treated with CON or FO ACM in this model (*p* \> 0.05, Figure [2](#F2){ref-type="fig"}).

mRNA Expression of M1 Markers and Associated Secreted Cytokines in Macrophages Treated With ACM in the Acute Inflammation Model {#S3-4}
-------------------------------------------------------------------------------------------------------------------------------

First, treating macrophages with low-dose LPS for 6 h (control) induced the expression of M1 markers and NLRP3 inflammasome-related genes shown in Figure [3](#F3){ref-type="fig"} relative to macrophages treated with just IgG (data not shown, *p* ≤ 0.05). Second, treating macrophages with either CON or FO ACM induced a response similar to endotoxin tolerance at the mRNA level as evidenced by decreased expression of M1 markers, *Nf*κ*b*, *Ccl2*, *Tnf*α, *Il6*, and *Ccl5*, as well as NLRP3 inflammasome-associated genes *Nlrp3*, *Il18*, and *Il1*β (Figure [3](#F3){ref-type="fig"}A, *p* ≤ 0.05). By contrast, macrophages treated with CON ACM had increased mRNA expression of *Nos2* relative to control (Figure [3](#F3){ref-type="fig"}A, *p* ≤ 0.05), whereas mRNA expression of *Casp1* in macrophages treated with CON or FO ACM did not differ from control (Figure [3](#F3){ref-type="fig"}A, *p* \> 0.05). Second, when anti-Ad was added, within each respective ACM group, the mRNA expression of M1 markers, *Nos2* (CON ACM only), *Tnf*α, *Il6*, and *Ccl5*, as well as NLRP3 inflammasome-related genes, *Casp1*, *Nlrp3*, and *Il18* (Figure [3](#F3){ref-type="fig"}A), decreased (*p* ≤ 0.05). By contrast, relative to each respective ACM treatment group, mRNA expression of *Il1*β increased with anti-Ad (*p* ≤ 0.05, Figure [3](#F3){ref-type="fig"}A). Third, mRNA expression of M1 genes, *Nos2* (FO ACM only), *Nf*κ*b*, and *Ccl2* decreased in macrophages treated with ACM regardless of adding anti-Ad (Figure [3](#F3){ref-type="fig"}A). Additionally, relative to CON ACM, macrophages treated with FO ACM had decreased mRNA expression of *Nos2*, *Nf*κ*b*, *Ccl2*, *Il6*, *Ccl2*, and *Il18* (*p* ≤ 0.05), although this effect was lost for *Nos2*, *Nf*κ*b*, *Ccl2*, and *Il18* with anti-Ad (*p* \> 0.05, Figure [3](#F3){ref-type="fig"}A). Fourth, secretion of IL-6 and CCL2 increased in both CON and FO ACM-treated macrophages relative to control; however, with anti-Ad, secretion of IL-6 and CCL2 (CON ACM only) returned to control levels (*p* \> 0.05, Figure [3](#F3){ref-type="fig"}B). Interestingly, in FO ACM-treated macrophages, secretion of CCL2 was elevated above all treatment groups, although this was partly subdued with anti-Ad (*p* ≤ 0.05, Figure [3](#F3){ref-type="fig"}B).

![**mRNA expression of M1 markers *Nos2*, *Nf*κ*b*, *Ccl2*, *Tnf*α, *Il6*, *Ccl5*, NLRP3 inflammasome genes (*Casp1*, *Il18*, and *Il1*β) (A), and secretion of M1-associated cytokines IL-6 and CCL2 (B) from macrophages treated with ACM ± anti-Ad in the acute inflammation model**. Macrophages were treated with CON or FO ACM (no LPS) for 18 h, followed by the addition of low-dose LPS (10 ng/mL) for the last 6 h (24 h total). 5 μg/mL of anti-Ad or IgG were added to ACM treatments prior to culture with macrophages. Macrophages treated with media with 5 μg/mL IgG plus LPS served as the control. Data show the means ± SEM (*n* = 5/diet/condition). Bars not sharing a letter are significantly different (*p* ≤ 0.05).](fnut-02-00031-g003){#F3}

mRNA Expression of M2 Markers and Secreted IL-10 in Macrophages Treated With ACM in the Acute Inflammation Model {#S3-5}
----------------------------------------------------------------------------------------------------------------

Treating macrophages with low-dose LPS for 6 h (control) induced mRNA expression of M2 markers, *Il10* and *Cd206*, and the antigen presentation co-stimulatory molecule, *Cd86*, relative to macrophages treated with just IgG (data not shown, *p* ≤ 0.05). Macrophages treated with CON ACM had decreased mRNA expression of *Il10* relative to control, while macrophages treated with both CON and FO ACM had decreased *Cd86* relative to control (*p* ≤ 0.05, Figure [4](#F4){ref-type="fig"}A). However, when anti-Ad was added to CON and FO ACM, mRNA expression of both *Il10* and *Cd206* were decreased (*p* ≤ 0.05, Figure [4](#F4){ref-type="fig"}A). Third, mRNA expression of *Cd86* in macrophages treated with FO ACM was decreased relative to CON ACM, though this effect was lost with anti-Ad (*p* ≤ 0.05, Figure [4](#F4){ref-type="fig"}A). Finally, IL-10 secretion was increased (*p* ≤ 0.05) in macrophages treated with CON ACM relative to control regardless of adding anti-Ad (Figure [4](#F4){ref-type="fig"}B). By contrast, IL-10 secretion decreased in macrophages treated with FO ACM relative to control and CON ACM (*p* ≤ 0.05), and this occurred regardless of adding anti-Ad (Figure [4](#F4){ref-type="fig"}B).

![**mRNA expression of M2-associated markers *Il10*, *Cd206*, and *Cd86* (A) and secretion of IL-10 (B) from macrophages treated with ACM ± anti-Ad in the acute inflammation model**. Macrophages were treated with CON or FO ACM (no LPS) for 18 h, followed by the addition of low-dose LPS (10 ng/mL) for the last 6 h (24 h total). 5 μg/mL of anti-Ad or IgG were added to ACM treatments prior to culture with macrophages. Macrophages treated with media and 5 μg/mL IgG + LPS served as the control. Data show the means ± SEM (*n* = 5/diet/condition). Bars not sharing a letter are significantly different (*p* ≤ 0.05).](fnut-02-00031-g004){#F4}

Lipid Profile in Macrophages Treated With ACM in the Chronic Inflammation Model {#S3-6}
-------------------------------------------------------------------------------

To examine if the Ad within ACM from CON or FO fed mice could affect macrophage phenotype in a chronic inflammation model, macrophages were treated with ACM collected from LPS-challenged visceral AT organ cultures or control media for 24 h with anti-Ad or control IgG. Additionally, within ACM samples, LPS was neutralized by polymyxin B (Px) to test if Ad worked synergistically with LPS. First, in macrophages treated with CON or FO ACM, we measured the relative abundance of neutral lipids after 24 h using oil red O staining and then quantified the percent of total n-3 and n-6 PUFA, MUFA and SFA relative to total fatty acid content (only showing those above 0.2% trace amounts of total lipid) (Figure [5](#F5){ref-type="fig"}). Interestingly, macrophages treated with CON ACM had similar neutral lipid relative to control; however, neutral lipid increased when Px, anti-Ad, or anti-Ad plus Px were added to CON ACM (*p* ≤ 0.05, Figure [5](#F5){ref-type="fig"}). By contrast, macrophages treated with FO ACM only had elevated levels of neutral lipid compared to control when anti-Ad or anti-Ad plus Px were added to FO ACM (*p* ≤ 0.05, Figure [5](#F5){ref-type="fig"}). Second, compared to macrophages treated with CON ACM, macrophages treated with FO ACM had increased total n-3 PUFA, n-6 PUFA and MUFA, while total SFA decreased (*p* ≤ 0.05, Figure [5](#F5){ref-type="fig"}). More specifically, macrophages treated with FO ACM had increased n-3 PUFA, including docosapentaenoic acid (DPA, 22:5 n-3) and docosahexaenoic acid (DHA, 22:6 n-3); increased n-6 PUFA, including linoleic acid (LA, 18:2 n-6) and arachidonic acid (AA, 20:4 n-6); and increased MUFA, including palmitoleic (16:1 c9), oleic (18:1 c9), and vaccenic (18:1 c11) acid (*p* ≤ 0.05, Figure [5](#F5){ref-type="fig"}). With regards to SFAs, macrophages treated with FO ACM also had increased myristic acid (14:0), while stearic acid (18:0) was decreased (*p* ≤ 0.05, Figure [5](#F5){ref-type="fig"}).

![**Neutral lipid uptake and total lipid profile in macrophages treated with ACM ± anti-Ad and Px in the chronic inflammation model**. Macrophages were treated with ACM from LPS-challenged CON or FO AT organ cultures for 24 h. 5 μg/mL of anti-Ad (or IgG) ± polymyxin B (36 μM; Px) were added to ACM treatments prior to culture with macrophages. Macrophages treated with media and 5 μg/mL IgG plus 10 ng/mL LPS ± Px served as the control. Data show the means ± SEM (*n* = 5/diet/condition). Bars not sharing a letter are significantly different (*p* ≤ 0.05). An asterisk indicates that the CON group is significantly different than the respective FO group (*p* ≤ 0.05).](fnut-02-00031-g005){#F5}

mRNA Expression of M1 Markers in Macrophages Treated With ACM in the Chronic Inflammation Model {#S3-7}
-----------------------------------------------------------------------------------------------

Treating macrophages with low-dose LPS for 24 h (control) induced the expression of M1 markers relative to macrophages treated with just IgG (data not shown, *p* ≤ 0.05), and adding Px to media with LPS suppressed this expression (*p* ≤ 0.05, Figure [6](#F6){ref-type="fig"}A). First, *Itgam* (CD11b) and *Nos2* were similarly expressed in control macrophages and macrophages treated with CON ACM; however, mRNA expression of *Nos2* decreased in FO ACM-treated macrophages (*p* ≤ 0.05, Figure [6](#F6){ref-type="fig"}A). Interestingly, with anti-Ad added, mRNA expression of *Itgam* in CON ACM increased above control levels (*p* ≤ 0.05, Figure [6](#F6){ref-type="fig"}A). Similarly, with anti-Ad in FO ACM, expression of *Nos2* increased to be similar to the control group (*p* \> 0.05, Figure [6](#F6){ref-type="fig"}A). Second, adding Px to ACM decreased mRNA expression of *Itgam* and *Nos2* in each respective ACM group; however, when both anti-Ad and Px were added to ACM, mRNA expression of *Itgam* and *Nos2* increased compared to each respective ACM group with Px (*p* ≤ 0.05, Figure [6](#F6){ref-type="fig"}A). Intriguingly, in the FO ACM treatment with anti-Ad and Px, mRNA expression of *Itgam* increased above all other treatment groups (*p* ≤ 0.05, Figure [6](#F6){ref-type="fig"}A). Finally, with regard to differences between CON and FO ACM groups, mRNA expression of *Nos2* was decreased in the FO ACM group even with Px or anti-Ad (*p* ≤ 0.05, Figure [6](#F6){ref-type="fig"}A).

![**mRNA expression of M1 markers *Itgam* and *Nos2* (A), associated cytokines *Tnf*α, *Il6*, and *Ccl2* (B), NLRP3 inflammasome genes *Nlrp3*, *Il18*, and *Il1*β (C), and key MHCII-related antigen presentation genes *Cd74*, *Cd80*, and *Cd86* (D) from macrophages treated with ACM ± anti-Ad and Px in the chronic inflammation model**. Macrophages were treated with ACM from LPS-challenged (10 ng/mL) CON or FO AT organ cultures for 24 h. 5 μg/mL of anti-Ad (or IgG) ± polymyxin B (36 μM; Px) were added to ACM treatments prior to culture with macrophages. Macrophages treated with media and 5 μg/mL IgG and 10 ng/mL LPS ± Px served as the control. Data show the means ± SEM (*n* = 5/diet/condition). Bars not sharing a letter are significantly different (*p* ≤ 0.05).](fnut-02-00031-g006){#F6}

Moreover, macrophages treated with CON ACM had decreased mRNA expression of *Tnf*α relative to control, although expression of *Il6* was similar to control, and expression of *Ccl2* was greater than control (*p* ≤ 0.05, Figure [6](#F6){ref-type="fig"}B). By contrast, macrophages treated with FO ACM had decreased mRNA expression of *Tnf*α and *Il6* relative to control (*p* ≤ 0.05), and expression of *Ccl2* was similar between these two groups (*p* \> 0.05, Figure [6](#F6){ref-type="fig"}B). Second, when anti-Ad was added to each respective ACM group, increased mRNA expression of *Il6* and *Ccl2* was observed in the FO ACM group only (*p* ≤ 0.05, Figure [6](#F6){ref-type="fig"}B). Third, adding Px to ACM decreased the mRNA expression of *Tnf*α, *Il6*, and *Ccl2* in each respective ACM group; however, when both anti-Ad and Px were added to ACM, mRNA expression of these cytokines significantly increased in each respective ACM group with Px (with the exception of *Tnf*α expression in the CON ACM group), (*p* ≤ 0.05, Figure [6](#F6){ref-type="fig"}B). Finally, with regards to differences between CON and FO ACM groups, mRNA expression of *Tnf*α and *Ccl2* decreased in the FO ACM group, even with Px added (*p* ≤ 0.05); however, this relationship was lost with the addition of anti-Ad and anti-Ad plus Px to FO ACM (*p* \> 0.05, Figure [6](#F6){ref-type="fig"}B).

mRNA Expression of NLRP3 Inflammasome Genes in Macrophages Treated With ACM in the Chronic Inflammation Model {#S3-8}
-------------------------------------------------------------------------------------------------------------

Treating macrophages with low-dose LPS for 24 h (control) induced the expression of NLRP3 inflammasome genes relative to macrophages treated with just IgG (data not shown, *p* ≤ 0.05), and adding Px to media with LPS (with the exception of *Il18*) suppressed this expression (*p* ≤ 0.05, Figure [6](#F6){ref-type="fig"}C). First, macrophages treated with CON ACM had increased mRNA expression of *Il18* relative to the control (*p* ≤ 0.05), whereas expression of *Nlrp3* was less than the control, and expression of *Il1*β was similar to control (*p* \> 0.05, Figure [6](#F6){ref-type="fig"}C). By contrast, macrophages treated with FO ACM had decreased mRNA expression of *Nlrp3* and *Il1*β relative to the control (*p* ≤ 0.05), and expression of *Il18* did not differ from control (*p* \> 0.05, Figure [6](#F6){ref-type="fig"}C). In each respective ACM group, adding anti-Ad resulted in increased mRNA expression of *Nlrp3* in both CON and FO ACM groups (*p* ≤ 0.05, Figure [6](#F6){ref-type="fig"}C). Adding Px in each respective CON or FO ACM group decreased mRNA expression of *Il18* and *Il1*β, although *Nlrp3* expression only decreased in the CON ACM group (*p* ≤ 0.05, Figure [6](#F6){ref-type="fig"}C). Interestingly, adding anti-Ad and Px to each respective CON or FO ACM group compared to ACM with just Px increased mRNA expression of *Nlrp3*, *Il18*, and *Il1*β (*p* ≤ 0.05, Figure [6](#F6){ref-type="fig"}C). Finally, with regards to differences between CON and FO ACM groups, mRNA expression of *Il18* and *Il1*β decreased with FO ACM, even with anti-Ad was added (*p* ≤ 0.05); however, this relationship was lost when anti-Ad plus Px were added to FO ACM (*p* \> 0.05, Figure [6](#F6){ref-type="fig"}C).

mRNA Expression of MHCII-Related Antigen Presentation Genes in Macrophages Treated With ACM in the Chronic Inflammation Model {#S3-9}
-----------------------------------------------------------------------------------------------------------------------------

Treating macrophages with low-dose LPS for 24 h (control) induced the expression of MHCII-related antigen presentation genes relative to macrophages treated with just IgG (data not shown, *p* ≤ 0.05), and adding Px to media with LPS (with the exception of *Cd74*) suppressed this expression (*p* ≤ 0.05, Figure [6](#F6){ref-type="fig"}D). First, macrophages treated with CON ACM had increased mRNA expression of *Cd80* relative to the LPS control (*p* ≤ 0.05), whereas expression of *Cd74* was similar to control (*p* \> 0.05), and expression of *Cd86* was less than control (*p* ≤ 0.05, Figure [6](#F6){ref-type="fig"}D). Moreover, macrophages treated with FO ACM had similar levels of *Cd74* and *Cd80* expression as the control (*p* \> 0.05), although expression of *Cd86* was less than the control (*p* ≤ 0.05, Figure [6](#F6){ref-type="fig"}D). Second, when anti-Ad was added, expression of MHCII-related genes only differed within each respective ACM group in one scenario; mRNA expression of *Cd80* increased in the FO ACM group (*p* ≤ 0.05, Figure [6](#F6){ref-type="fig"}D). Third, adding Px to each respective ACM group decreased mRNA expression of *Cd80* and *Cd86* in both CON and FO ACM (*p* ≤ 0.05). Interestingly, when anti-Ad plus Px were added to each respective ACM group, mRNA expression of *Cd74*, *Cd80*, and *Cd86* increased compared to ACM with Px or anti-Ad alone (with the exception of *Cd80* expression in CON ACM with anti-Ad relative to CON ACM with anti-Ad and Px) (*p* ≤ 0.05, Figure [6](#F6){ref-type="fig"}D). Finally, with regards to differences between CON and FO ACM groups, FO ACM groups had decreased mRNA expression of *Cd74* (between Px groups only), *Cd80* (between IgG and anti-Ad groups only), and *Cd86* (between IgG groups only), (*p* ≤ 0.05, Figure [6](#F6){ref-type="fig"}D).

Secretion of Cytokines in Macrophages Treated With ACM in the Chronic Inflammation Model {#S3-10}
----------------------------------------------------------------------------------------

First, secretion of all of the aforementioned cytokines increased in LPS-treated macrophages after 24 h compared to the IgG control (*p* ≤ 0.05, data not shown). Second, adding Px to the LPS control decreased secretion of all of the aforementioned cytokines (*p* ≤ 0.05, Figure [7](#F7){ref-type="fig"}). Third, relative to control macrophages, those treated with CON ACM had increased secretion of IL-6 and CCL2 (*p* ≤ 0.05), whereas TNFα was similar (*p* \> 0.05), and secretion of IL-10 was less than the control (*p* ≤ 0.05, Figure [7](#F7){ref-type="fig"}). Moreover, compared to control, in FO ACM, secretion of CCL2 was similar, IL-6 was greater, and TNFα and IL-10 were decreased (*p* ≤ 0.05, Figure [7](#F7){ref-type="fig"}). Fourth, when anti-Ad was added to each respective ACM group, the secretion of CCL2 increased in both CON and FO ACM, whereas secretion of TNFα increased in the CON ACM group only (*p* ≤ 0.05, Figure [7](#F7){ref-type="fig"}). Fifth, when Px was added to each respective ACM group, secretion of TNFα increased in the FO ACM group, whereas IL-10 secretion decreased in both the CON and FO ACM group (*p* ≤ 0.05), and secretion of IL-6 and CCL2 did not change (*p* \> 0.05, Figure [7](#F7){ref-type="fig"}). Sixth, with regards to differences between CON and FO ACM groups, FO ACM groups had decreased secretion of IL-6 and CCL2 even when Px (with the exception of CCL2), anti-Ad, or anti-Ad plus Px were added to ACM (*p* ≤ 0.05, Figure [7](#F7){ref-type="fig"}). Interestingly, when anti-Ad was added to ACM there was a decrease in secretion of TNFα and IL-10 in the FO ACM group compared to the CON ACM group (*p* ≤ 0.05); however, this effect was lost for TNFα when anti-Ad plus Px were added to FO ACM (*p* \> 0.05, Figure [7](#F7){ref-type="fig"}).

![**Secretion of M1-associated cytokines (IL-6, CCL2, and TNFα) and anti-inflammatory cytokine, IL-10 from macrophages treated with ACM ± anti-Ad and Px in the chronic inflammation model**. Macrophages were treated with ACM from LPS-challenged (10 ng/mL) CON or FO AT organ cultures for 24 h. 5 μg/mL of anti-Ad (or IgG) ± polymyxin B (36 μM; Px) were added to ACM treatments prior to culture with macrophages. Macrophages treated with media and 5 μg/mL IgG and 10 ng/mL LPS ± Px served as the control. Data show the means ± SEM (*n* = 5/diet/condition). Bars not sharing a letter are significantly different (*p* ≤ 0.05).](fnut-02-00031-g007){#F7}

Discussion {#S4}
==========

Although it was known that LC n-3 PUFA modulate adipocyte--macrophage paracrine interactions ([@B23], [@B24]), as well as the AT secretory profile in obese mice ([@B25]), the effect of LC n-3 PUFA on the intact AT secretory profile and how this subsequently affects macrophage polarization status was not known. Thus, we generated visceral ACM from mice fed a CON (n-6 PUFA-rich) or FO (LC n-3 PUFA-rich) diet and then examined its effects on macrophage phenotype under different stimulation conditions designed to mimic aspects of the AT microenvironment. Specifically, we utilized two models: an acute inflammation model to assess if pre-treating macrophages with ACM could promote a response similar to endotoxin tolerance in macrophages when stimulated with low-dose LPS and a low-grade chronic inflammation model wherein AT organ cultures were challenged with LPS to make ACM prior to incubation with macrophages to mimic the inflammatory state that occurs in parallel with metabolic endotoxemia ([@B11], [@B33]). Here, we report for the first time that in the acute inflammation model, macrophages treated with FO ACM had decreased lipid uptake (Figure [2](#F2){ref-type="fig"}), and mRNA expression of M1-associated markers (*Nos2*, *Nf*κ*b*, *Il6*, *Il18*, *Ccl2*, and *Ccl5*, Figure [3](#F3){ref-type="fig"}) compared with CON ACM; however, these effects were largely attenuated when Ad was neutralized, indicating that Ad is an important factor in LC n-3 PUFA-mediated effects. Furthermore, intact AT from mice fed CON or FO diets differed in the secretory response to a low-grade LPS challenge, as evidenced by decreased IL-6, CCL2, CCL5, and CCL7 secreted from FO ACM (Figure [1](#F1){ref-type="fig"}). Additionally, in the chronic inflammation model, compared to CON ACM, macrophages treated with FO ACM had decreased mRNA expression of M1-associated markers (*Nos2*, *Tnf*α, *Ccl2*, *Il1*β*, Cd80*, and *Cd86*, Figure [6](#F6){ref-type="fig"}) and IL-6 and CCL2 secretion (Figure [7](#F7){ref-type="fig"}); some of these effects were lost when Ad was neutralized, and were further exacerbated when both Ad and LPS were neutralized. Taken together, this work provides evidence that LC n-3 PUFA and Ad may work in concert to suppress specific M1 macrophage responses in a microenvironment representative of AT.

Intriguingly, the results suggest that the anti-inflammatory effects of LC n-3 PUFA in macrophages may be partly due to Ad-mediated signaling, which, to the best of our knowledge, has not been previously reported. Although previous studies have shown that LC n-3 PUFA increase circulating Ad in rodents ([@B43], [@B44]) and humans ([@B45], [@B46]), the current study did not find any changes in secreted levels of full-length Ad in ACM due to diet or LPS exposure (Figure [1](#F1){ref-type="fig"}B). This may have occurred because the 24 h *ex vivo* period used to generate ACM was not long enough to induce changes in the levels of Ad secreted from the AT organ cultures; however, this requires further study. Nonetheless, some of the anti-inflammatory effects of FO ACM on macrophages in both the acute and chronic inflammation models were lost when Ad was neutralized. For example, in the acute model, lipid uptake increased back to control level in FO ACM-treated macrophages when Ad was neutralized in LPS-challenged cells (Figure [2](#F2){ref-type="fig"}). Decreasing lipid uptake may be a mechanism by which LC n-3 PUFA act to decrease excessive M1 macrophage responses in obese AT since lipotoxicity in macrophages is thought to be a key driver of M1 macrophage polarization ([@B47]). Second, in the chronic inflammation model, compared to LPS control, the FO ACM-mediated decrease in mRNA expression of M1-associated markers (*Nos2*, *Ccl2*, *Nlrp3*, and *Cd80*, Figure [6](#F6){ref-type="fig"}) and secretion of CCL2 (Figure [7](#F7){ref-type="fig"}) was lost when Ad was neutralized. Taken together, this data suggest that Ad plays a role in LC n-3 PUFA-mediated anti-inflammatory effects in macrophages, such as buffering lipid uptake and mRNA expression of specific markers associated with the M1 macrophage phenotype.

Another novel finding in the current study was our data showing that Ad may work synergistically with LPS to decrease macrophage mRNA expression of M1 markers, particularly in FO ACM-treated macrophages in the chronic inflammation model. Specifically, M1 markers (*Itgam*, *Il6*, Figures [6](#F6){ref-type="fig"}A,B), NLPR3 inflammasome genes (*Nlrp3*, *Il18*, *Il1*β, Figure [6](#F6){ref-type="fig"}C), MHCII-related antigen presentation genes (*Cd74*, *Cd80*, *Cd86*, Figure [6](#F6){ref-type="fig"}D), as well as secretion of IL-6 and TNFα (Figure [7](#F7){ref-type="fig"}), further increased compared to FO ACM with anti-Ad when both anti-Ad plus the LPS-neutralizing agent, polymyxin B, were added. Along these lines, Park et al. ([@B18], [@B48]) showed that globular Ad initially triggers signaling cascades that result in activation of NFκB and subsequent TNFα mRNA expression; however, 5 h post-induction, this triggered a compensatory anti-inflammatory response resulting in IL-10 secretion and subsequent desensitization when re-stimulated with LPS. Thus, Ad may have immunoregulating properties in response to an inflammatory stimulus, such as LPS, which warrants greater characterization, particularly in FO ACM-treated macrophages where some of the anti-inflammatory effects of Ad were negated when both Ad and LPS were blocked. Indeed, future studies silencing adiponectin signaling in primary macrophages would be an effective strategy to delineate if adiponectin plays a role in the immunomodulatory activity of LC n-3 PUFA in macrophages.

Interestingly, in the acute inflammation model, neutralizing Ad in both CON and FO ACM led to a decrease in mRNA expression of several M1-associated markers (*Tnf*α, *Il6*, *Ccl5*, Figure [3](#F3){ref-type="fig"}A; NLRP3 inflammasome genes *Nlrp3*, *Casp1*, *Il18*, Figure [3](#F3){ref-type="fig"}A; secretion of IL-6 and CCL2, Figure [3](#F3){ref-type="fig"}B), as well as a decrease in expression of M2 markers (*Il10* and *Cd206*, Figure [4](#F4){ref-type="fig"}). This data suggest that Ad promotes mRNA expression of both M1 and M2 genes in ACM, which is in line with a previous report showing that M1 macrophages treated with Ad showed more robust inflammatory cytokine secretion (e.g., IL-6), and M2 polarized macrophages treated with Ad showed more robust IL-10 secretion ([@B19]). This relationship requires further study *in vivo* especially given that a recent study in obese mice showed Ad accumulation in AT stroma vascular cells, including macrophages ([@B49]), further suggesting that Ad could potentially promote more robust M1 and M2 macrophage polarization in obese AT.

Our findings that FO ACM had marked anti-inflammatory effects in macrophages compared to CON ACM in both the acute and chronic inflammation models are in agreement with other studies showing that LC n-3 PUFA decrease the degree of M1 macrophage polarization in the chronically inflamed obese AT microenvironment *in vivo* ([@B26]--[@B29], [@B50]). Notably, compared to CON ACM generated from AT organ cultures, FO ACM had decreased secreted protein levels of IL-6, CCL2, CCL5, and CCL7 (Figure [5](#F5){ref-type="fig"}). Second, compared to CON ACM, FO ACM decreased mRNA expression of M1-associated markers in macrophages, including *Nos2*, *Nf*κ*b*, *Il6*, *Il18*, *Ccl2*, and *Ccl5* in the acute model (Figure [3](#F3){ref-type="fig"}A). Third, compared to CON ACM, FO ACM decreased mRNA expression of M1 markers (*Nos2*, *Tnf*α, *Ccl2*, *Il18*, *Il1*β, *Cd80*, and *Cd86*, Figure [6](#F6){ref-type="fig"}) and secretion of IL-6 and CCL2 in the chronic inflammation model (Figure [7](#F7){ref-type="fig"}), and this occurred concurrently with changes in the macrophage lipid profile. Notably, macrophage LC n-3 PUFA, such as DPA and DHA increased, while SFA, such as stearic acid, decreased (Figure [5](#F5){ref-type="fig"}). This data show that LC n-3 PUFA are released from AT within ACM and that these fatty acids are subsequently taken up by macrophages. This is not surprising since n-3 PUFA-fed animals and humans exhibit increased AT n-3 PUFA storage and mobilization \[reviewed by Raclot ([@B51])\]. Additionally, TLR4 stimulation causes DHA and EPA pre-treated macrophages to secrete these PUFA as free fatty acids ([@B52]), which represents a potential mechanism by which LC n-3 PUFA distribute themselves among macrophages to mitigate excessive inflammatory responses. Furthermore, this change in macrophage lipid profile could partly explain some of the anti-inflammatory effects observed after treating macrophages with FO ACM. After LC n-3 PUFA are taken up by macrophages, the subsequent anti-inflammatory effects may be partly due to their incorporation into the phospholipid fraction of cellular membranes where they can act to decrease the signaling efficiency of protein complexes localized in small, hydrophobic membrane microdomains called lipid rafts ([@B53], [@B54]), including the TLR4 complex ([@B55]); however, this relationship requires further study in ACM models.

Treating macrophages with FO ACM also led to changes in macrophage mRNA expression of MHCII-related antigen presentation genes. Specifically, compared to CON ACM, macrophages treated with FO ACM had decreased mRNA expression of co-stimulatory molecules, including *Cd86* in the acute inflammation model (Figure [4](#F4){ref-type="fig"}), and *Cd80* and *Cd86* (Figure [6](#F6){ref-type="fig"}D) in the chronic inflammation model. This data complements previous research showing that LC n-3 PUFA decrease antigen presenting cell-mediated co-stimulatory molecule mRNA and surface expression ([@B56], [@B57]). Moreover, globular ([@B16], [@B18]) and full-length ([@B15], [@B58]--[@B60]) Ad promote IL-10 secretion from macrophages. IL-10 represses co-stimulatory molecule expression on antigen presenting cells ([@B61]), suggesting that the Ad-IL-10 axis may affect antigen presenting cell functions. In this study, FO ACM-treated macrophages did not upregulate IL-10 mRNA expression or secretion, suggesting that the FO-mediated decrease in mRNA expression of *Cd80* and *Cd86* occurs independently of IL-10 in this model. Overall, this data provide preliminary evidence that FO may mitigate antigen presentation in macrophages \[key antigen presenting cells in obese AT ([@B9], [@B62], [@B63])\] by decreasing co-stimulatory molecule expression; however, this relationship requires further study.

In summary, we showed for the first time that ACM promotes a response similar to endotoxin tolerance in macrophages and that macrophages treated with FO ACM had decreased lipid uptake and expression of markers associated with an inflammatory M1 phenotype compared to CON ACM in both the acute and chronic inflammation models. Importantly, the anti-inflammatory effect of FO ACM on suppressing lipid uptake and M1 marker expression in macrophages was partly lost when Ad was neutralized in FO ACM. Overall, our data suggests that Ad and LC n-3 PUFA work together to affect the macrophage phenotype in a microenvironment representative of obese AT. Additionally, this relationship warrants further study *in vivo* to further understand the role of dietary LC n-3 PUFA in mitigating obese AT inflammation and related pathologies.

Author Contributions {#S5}
====================

AD, JM, and LR designed the research; AD, JM, and DL conducted the research; AD analyzed the data; AD and LR wrote the paper and had primary responsibility for the final content; DM and KP provided the animals and expertise. All authors read and approved the final manuscript.

Conflict of Interest Statement {#S6}
==============================

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Funding {#S7}
=======

This work was supported by the Natural Sciences and Engineering Research Council of Canada (NSERC) and Agriculture and Agri-Food Canada. AB was supported by a College of Biological Sciences PhD award at the University of Guelph and a NSERC PGSD scholarship. DL was supported by an Ontario Graduate Scholarship.

Abbreviations {#S8}
=============

ACM, adipose tissue conditioned media; Ad, adiponectin; AT, adipose tissue; ATM, adipose tissue macrophage; CD, cluster of differentiation; CCL, chemokine (c--c motif) ligand; CON, control; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; FO, fish oil; IL, interleukin; iNOS, inducible nitric oxide synthase; LC n-3 PUFA, long-chain n-3 polyunsaturated fatty acids; LF, low-fat; LPS, lipopolysaccharide; NFκB, nuclear factor kappa-light-chain-enhancer of activated B cells; NLRP, NOD-like receptor family, Pyrin domain containing; PBS, phosphate buffered saline; Px, polymyxin B; ROS, reactive oxygen species; TLR, toll-like receptor; TNFα, tumor necrosis factor alpha.

[^1]: Edited by: Philip Calder, University of Southampton, UK

[^2]: Reviewed by: Naima Moustaid-Moussa, Texas Tech University, USA; Kate J. Claycombe, United States Department of Agriculture, USA; Harry Wichers, Wageningen University and Research Centre, Netherlands

[^3]: Specialty section: This article was submitted to Nutritional Immunology, a section of the journal Frontiers in Nutrition
